The Cardioband mitral system is designed to safely and effectively reduce mitral
regurgitation through annular reduction.

Mitral regurgitation:
Treatment is complex and options are limited

Mitral regurgitation (MR) occurs in approximately 2% of the population, with up to 10% of people over 75 years old affected.1

Medically managed patients with severe MR have poor outcomes.2

Outcomes of severe MR chart

Individualised annular reduction

A CE Mark-approved transcatheter device designed to safely and effectively reduce mitral regurgitation through annular reduction3

Restores valve to a more functional state, facilitating leaflet coaptation

Enables annular reduction based on each patient’s anatomy

Supports real-time adjustment and confirmation of procedural results

A proven transseptal approach

The Cardioband mitral system is a transcatheter device designed to restore the mitral valve to a more functional state, facilitating leaflet coaptation and reducing mitral regurgitation.

  • Access

    The Cardioband delivery system is inserted into the left ventricle using a transseptal approach.
  • Deploy

    individual anchors in a systematic, step-wise approach to conform the Cardioband implant to each patient's anatomy.
  • Adjust and confirm

    MR reduction in real time via transesophageal echo (TEE).

Excellent outcomes

Cardioband mitral system shows excellent outcomes in the CE Mark trial.4,5

Sustained survival

Kaplan-Meier analysis

MR reduction

*Courtesy of Dr. Paul Grayburn, Baylor University, Houston, Texas, USA.

Annular reduction

Functional improvement

aMcNemar's test
bT-test
6MWT = 6-Minute Walk Test; MLHFQ = Minnesota Living with Heart Failure Questionnaire

Reduce the annulus. Restore her potential.

Learn more

Learn more about the Cardioband mitral system.

Cardioband Mitral System Product Brochure

Cardioband mitral system product brochure

Download brochure (PDF)
Cardioband Mitral System Brochure

Cardioband mitral system
2-year data

Download brochure (PDF)

Video library

Cardioband mitral system procedure animation

Two-year Cardioband mitral system data at PCR London Valves 2018

Two-year Cardioband mitral system data at PCR London Valves 2018

Register for Cardioband mitral system updates

Sign up now to receive event information and news information from Edwards Lifesciences including:

  • Publications
  • Congress highlights
  • Webinar invites
  • Product announcements and updates

Learn more about Edwards' transcatheter mitral and tricuspid portfolio

Makeamark icon

MakeAMark.com

Get to know all of our transformational mitral and tricuspid therapies

Learn more
References:
  1. Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368:1005-1011.
  2. Goel SS, Bajaj N, Aggarwal B, et al. Prevalence and outcomes of unoperated patients with severe symptomatic mitral regurgitation and heart failure: comprehensive analysis to determine the potential role of MitraClip for this unmet need. J Am Coll Cardiol. 2014;63:185-186.
  3. Vahanian A. Multicentre trial results of the transcatheter mitral valve repair system for functional mitral regurgitation. Presented at PCR London Valves, 2017.
  4. Transcatheter mitral valve repair in patients with functional mitral regurgitation: 2 year follow-up of the multicenter CE trial. Presented by Francesco Maisano, MD, PCR London Valves, 2018.
  5. Nickenig G. et al. Transcatheter Mitral Annuloplasty in Chronic Functional Mitral Regurgitation - 6-Month Results With the Cardioband Percutaneous Mitral Repair System. J Am Coll Cardiol Intv 2016;9:2039–47.

For professional use

For professional use. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

For professional use

For professional use. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

Edwards Lifesciences devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity. Cardioband Systems are manufactured by Valtech Cardio Ltd. for Edwards Lifesciences.

Material for distribution only in countries with applicable health authority product registrations. Material not intended for distribution in USA or Japan.

Edwards, Edwards Lifesciences, the stylized E logo and Cardioband are trademarks of Edwards Lifesciences Corporation or its affiliates.

© 2018 Edwards Lifesciences Corporation. All rights reserved. E8576/10-18/TMTT

Edwards Lifesciences • Route de l’Etraz 70, 1260 Nyon, Switzerland • edwards.com

Please update your browserClose this window

Please update to a current version of your preferred browser, this site will perform effectively on the following:

Unable to update your browser?

If you are on a computer, that is maintained by an admin and you cannot install a new browser, ask your admin about it. If you can't change your browser because of compatibility issues, think about installing a second browser for browsing and keep this old one for compatibility